Log In
BCIQ
Print this Print this
 

ophthalmic TRC105 (DE-122)

  Manage Alerts
Collapse Summary General Information
Company Tracon Pharmaceuticals Inc.
DescriptionHuman chimeric mAb against endoglin (CD105; ENG)
Molecular Target Endoglin (CD105) (ENG)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD)
Regulatory Designation
PartnerSanten Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$10.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/10/2014

Undisclosed

$10.0M

Undisclosed

Get a free BioCentury trial today